Last updated October 21, 2026. Approval line checked October 21, 2026. No compounding source date is assigned.
FDA status
Investigational
Investigational. No FDA-approved cibinetide product is recorded for this entry. It has been studied in clinical trials.
ClinicalTrials.gov: cibinetideBy signing up you agree to get PeptideX update emails. Unsubscribe anytime. Educational only, not medical advice.
Evidence tier
Human RCT. The tier is the highest indexed study type. It is not a safety rating and it is not an FDA approval. Confidence score 4/5. 59 PubMed citations indexed.
ARA-290 is an 11-amino-acid non-hematopoietic peptide engineered from the helix B surface domain of erythropoietin that selectively activates a heterodimeric innate repair receptor (EPOR/β-common rece
What the literature studies
Immune Research
Evidence tier
Human RCT
Compounding record
Status not verified
Status not verified. No product-specific FDA primary source is recorded for this entry. FDA approval and compounding eligibility are not verified. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route.
Regulatory source not verified; no checked date is assigned.
Regulatory context and verification limits are documented below.
By signing up you agree to get PeptideX update emails. Unsubscribe anytime. Educational only, not medical advice.
Educational only. Not medical advice. This page does not give doses or sourcing. See the medical and editorial disclaimer.